Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 February 2024 | Story VALENTINO NDABA | Photo SUPPLIED
Dr Jacques Matthee
Dr Jacques Matthee, was recently appointed the new Vice-Dean at the Faculty of Law.

In the dynamic landscape of academia, where traditional methodologies intersect with digital advancements, Dr Jacques Matthee stands out as a beacon of innovation and change. Recently assuming the role of Vice-Dean for Learning, Teaching, Innovation, and Digitalisation at the Faculty of Law, University of the Free State (UFS), Dr Matthee brings with him a profound dedication to knowledge, a passion for transformation, and a clear vision for the future of legal education.

With a distinguished academic background, including qualifications in LLB, LLM, and LLD, Dr Matthee has established himself as an expert in areas such as Legal Pluralism, African Customary Law, Criminal Law, and Medical Law. However, it is not just his credentials that distinguish him; it is his unwavering commitment to the pursuit of knowledge that sets him apart.

Pursuing knowledge: A lifelong passion

Reflecting on his childhood aspirations, Dr Matthee recalls dreaming of becoming a detective – a fascination that eventually led him to the realm of law. Over time, his interest in law deepened, propelling him towards his current position as a leading figure in legal academia. Yet, Dr Matthee’s ambitions extend beyond conventional success. In 2023, he surprised many by participating in his first-ever fitness event, demonstrating a determination to challenge himself beyond the boundaries of his profession. This blend of dedication, discipline, and integrity not only characterises his personal pursuits but also informs his professional endeavours.

Charting new horizons: The Vice-Dean's vision

Assuming the role of Vice-Dean for Learning, Teaching, Innovation, and Digitalisation, Dr Matthee enters uncharted territory. "It is a new position, not only within the faculty but also at UFS," he explains. "There is no model or blueprint to guide us." However, it is precisely this challenge that excites him the most. With autonomy in his role, Dr Matthee sees an opportunity to shape the future of legal education by pioneering initiatives that integrate traditional pedagogy with cutting-edge digital advancements.

"I look forward to the challenge of creating such a blueprint," Dr Matthee remarks. "Moreover, the position will allow me to explore and introduce exciting initiatives that could make a meaningful impact on the future and direction of teaching and learning in the faculty."

For Dr Matthee, the future of legal education lies not only in embracing innovation but also in cultivating an environment where curiosity thrives and knowledge knows no bounds. Under his leadership, the Faculty of Law at UFS is poised to embark on a transformative journey, where learning, teaching, and innovation converge to shape the legal minds of tomorrow.

In Dr Jacques Matthee, the UFS Faculty of Law finds not just a Vice-Dean, but a visionary dedicated to pushing boundaries, challenging norms, and sculpting a future where the pursuit of knowledge knows no limits. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept